Mylan Inc. said its Matrix Laboratories unit received Food and Drug Administration approval to market a generic version of Pfizer Inc.''s drug Neurontin, according to the Associated Press. Neurontin was originally approved as a treatment for seizures and more recently cleared for pain caused by shingles. The generic name for the drug is gabapentin. Mylan received approval to market 100-milligram, 300-milligram, and 400-milligram doses of the capsules. The company said the drug had $300 million in sales for the 12-month period ending Dec. 31, according to IMS Health. Mylan plans to launch the generic version immediately.